ACCESS: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

with a MMUD using stem cells from a donor’s blood [instead of using the donor’s bone marrow]. An allogeneic stem cell transplant is a standard treatment for blood cancers. An allogeneic transplant replaces your abnormal (or diseased) blood cells with healthy blood-making cells from a donor. We’re doing this study to see how well transplant works in adults with a MMUD using stem cells from a donor’s blood. This study treatment does not include any investigational drugs.

Are you Eligible? (Inclusion Criteria)

• Donor:
• 1. Are you 18 year of age or older and younger then 36?
• 2. Are you willing and able to donate peripheral blood stem cells?
• Recipient:
• 1. Are you 18 years of age or older?
• 2. Have you been diagnosed with any of the following: acute leukemia, MDS,
• chronic myelogenous leukemia, or lymphoma with chemosensitive disease?
• 3. Is your liver functional?